IMMU-114: Phase I data

Data from 6 evaluable patients with NHL or CLL in an open-label, dose-escalation, U.S. Phase I trial showed that twice-weekly subcutaneous 200 mg IMMU-114 led to 1 complete response and 3 partial resp...